TriangleNCT04971226 · OUTCOME
PK of Asciminib: CL/F
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- ng*hr/mL
- Interval / dispersion
- Geometric Coefficient of Variation
- Time frame
- Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)
What was measured
CL/F is the apparent total body clearance of asciminib from plasma after oral administration (volume x time-1).
Analysis population: Although samples were collected for 26 participants, CL/F could not be evaluated because extrapolated AUC was over 20% for all participants. CL/F is derived from extrapolated AUC. However, when it is over 20% for all participants, CL/F cannot be determined.
Groups in this outcome
Asciminib (All Asciminib)
Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.
| Group | Source count |
|---|---|
| Asciminib (All Asciminib) | 26 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Asciminib (All Asciminib) | NA | NA | Not reported | Not reported | Although samples were collected for 26 participants, CL/F could not be evaluated because extrapolated AUC was over 20% for all participants. CL/F is derived from extrapolated AUC. However, when it is over 20% for all participants, CL/F cannot be determined. |
Complete source fields
- classes
- categories
- measurements
- comment
- Although samples were collected for 26 participants, CL/F could not be evaluated because extrapolated AUC was over 20% for all participants. CL/F is derived from extrapolated AUC. However, when it is over 20% for all participants, CL/F cannot be determined.
- group Id
- OG000
- spread
- NA
- value
- NA
- denoms
- counts
- group Id
- OG000
- value
- 26
- units
- Participants
- description
- CL/F is the apparent total body clearance of asciminib from plasma after oral administration (volume x time-1).
- dispersion Type
- Geometric Coefficient of Variation
- groups
- description
- Patients took asciminib 80 mg QD under fasting conditions on ongoing basis.
- id
- OG000
- title
- Asciminib (All Asciminib)
- param Type
- GEOMETRIC_MEAN
- population Description
- Although samples were collected for 26 participants, CL/F could not be evaluated because extrapolated AUC was over 20% for all participants. CL/F is derived from extrapolated AUC. However, when it is over 20% for all participants, CL/F cannot be determined.
- reporting Status
- POSTED
- time Frame
- Week 2 (0 hours (h) pre-dose, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose)
- title
- PK of Asciminib: CL/F
- type
- SECONDARY
- unit Of Measure
- ng*hr/mL
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice